This clinical trial is focused on studying the detection of Gamma-Hydroxybutyrate (GHB), a substance sometimes involved in cases of intoxication, such as drug-facilitated crimes. The study aims to improve methods for detecting GHB in the body by identifying potential biomarkers, which are substances that can indicate the presence of GHB for a longer period than GHB itself. The trial involves healthy volunteers who will be given sodium oxybate, an oral solution that is chemically similar to GHB, to help researchers understand how long these biomarkers can be detected in the body.

Participants in the study will receive either the active treatment, which is sodium oxybate, or a placebo. The study will also involve the use of sodium chloride and paracetamol as part of the research process. Sodium chloride is a common salt solution, and paracetamol is a widely used pain reliever. The purpose of the study is to see how long the biomarkers can be detected in different body fluids and tissues, such as blood, urine, oral fluid, hair, and even dental calculus, which is the hardened plaque on teeth.

The study will monitor various aspects, including the concentration of GHB and the identified biomarkers in these samples over time. Additionally, the study will assess the effects of the drug on memory and physical appearance shortly after intake. This research is important for developing better ways to detect GHB in situations where it may have been used without a person’s knowledge, helping to improve safety and justice in such cases.